MarketLens
Sign Up

AbbVie's Post-Humira Triumph: Skyrizi and Rinvoq Drive Sector-Leading Growth

4 months ago
SHARE THIS ON:

AbbVie's Post-Humira Triumph: Skyrizi and Rinvoq Drive Sector-Leading Growth

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•3 weeks ago

AbbVie: Why I See More Upside After Q3

AbbVie's Q3 revenue rose 10.3% YoY and non-GAAP EPS jumped 105.4%, driven by strong results including Skyrizi sales of $5.78B, up 22.7% YoY.
Stock News•2 months ago

AbbVie's Immunology Franchise: From Skyrizi & Rinvoq to What's Next

AbbVie's immunology franchise is being driven by Skyrizi and Rinvoq, with new indications, acquisitions, and partnerships building the next wave of growth.
Stock News•3 months ago

ABBV Q2 Earnings Call Balances Growth With Apogee Dilution

AbbVie raised 2026 revenue guidance on Skyrizi, Rinvoq and neuroscience growth, while the Apogee deal trims EPS guidance and lifts R&D spending.

Breaking News

View All →

Top Headlines

View More →
Stock News•2 hours ago

Cisco Stock Fell 15.5% Despite Its Strongest Growth in 15 Years. Is the Dividend Safe?

Stock News•2 hours ago

Prediction: This Will Be Nvidia's Stock Price in 2027 After Its Phenomenal Q3 Results

Stock News•2 hours ago

GOOGL, GOOG FINAL DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages Alphabet Inc. Investors to Secure Counsel Before Important December 1 Deadline in Securities Class Action - GOOGL, GOOG

Stock News•3 hours ago

The S&P 500 Is Now Below Every Wall Street Year-End Target for 2026

Stock News•3 hours ago

The S&P 500 Is Having the Longest Losing Streak Since February 2020